GABELLI HEALTHCARE & WELL (GRX)
US36246K1034
We assign a fundamental rating of 2 out of 10 to GRX. GRX was compared to 0 industry peers in the Unkown industry. The financial health of GRX is average, but there are quite some concerns on its profitability. GRX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
GRX had negative earnings in the past year.
GRX had a positive operating cash flow in the past year.
GRX had positive earnings in 4 of the past 5 years.
In multiple years GRX reported negative operating cash flow during the last 5 years.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.53% | ||
| ROE | 2.03% | ||
| ROIC | N/A |
ROA(3y)-2.24%
ROA(5y)3.37%
ROE(3y)-2.25%
ROE(5y)3.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GRX's Profit Margin has declined in the last couple of years.
GRX does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 97.14% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-74.13%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
GRX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for GRX has been reduced compared to 5 years ago.
Compared to 1 year ago, GRX has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 1.84 indicates that GRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
GRX has a debt to FCF ratio of 1.74. This is a very positive value and a sign of high solvency as it would only need 1.74 years to pay back of all of its debts.
GRX has a Debt/Equity ratio of 0.32. This is a healthy value indicating a solid balance between debt and equity.
Although GRX does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.32 | ||
| Debt/FCF | 1.74 | ||
| Altman-Z | 1.84 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 2.00 indicates that GRX should not have too much problems paying its short term obligations.
GRX has a Quick Ratio of 2.00. This is a normal value and indicates that GRX is financially healthy and should not expect problems in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2 | ||
| Quick Ratio | 2 |
3. Growth
3.1 Past
GRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 100.10%, which is quite impressive.
The earnings per share for GRX have been decreasing by -72.17% on average. This is quite bad
GRX shows a decrease in Revenue. In the last year, the revenue decreased by -1.94%.
Measured over the past years, GRX shows a decrease in Revenue. The Revenue has been decreasing by -5.01% on average per year.
EPS 1Y (TTM)100.1%
EPS 3Y-72.17%
EPS 5YN/A
EPS Q2Q%-618.05%
Revenue 1Y (TTM)-1.94%
Revenue growth 3Y4.21%
Revenue growth 5Y-5.01%
Sales Q2Q%-10.6%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.08 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 6.19%, GRX is a good candidate for dividend investing.
GRX's Dividend Yield is rather good when compared to the S&P500 average which is at 2.30.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 6.19% |
5.2 History
GRX has paid a dividend for at least 10 years, which is a reliable track record.
GRX has decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years2
5.3 Sustainability
402.46% of the earnings are spent on dividend by GRX. This is not a sustainable payout ratio.
DP402.46%
EPS Next 2YN/A
EPS Next 3YN/A
GABELLI HEALTHCARE & WELL
NYSE:GRX (12/30/2024, 12:04:32 PM)
After market: 9.73 +0.12 (+1.25%)9.61
-0.09 (-0.93%)
Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)
Earnings (Next)
Inst Owners33.17%
Inst Owner Change5.59%
Ins Owners1.74%
Ins Owner Change3.61%
Market Cap149.92M
Analysts0
Price TargetN/A
Short Float %0.09%
Short Ratio0.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 6.19% |
Dividend Growth(5Y)N/A
DP402.46%
Div Incr Years0
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 35.78 | ||
| P/FCF | 4.08 | ||
| P/OCF | 4.08 | ||
| P/B | 0.75 | ||
| P/tB | 0.75 | ||
| EV/EBITDA | N/A |
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)2.36
FCFY24.51%
OCF(TTM)2.36
OCFY24.51%
SpS0.27
BVpS12.86
TBVpS12.86
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.53% | ||
| ROE | 2.03% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 97.14% | ||
| GM | N/A | ||
| FCFM | 877.09% |
ROA(3y)-2.24%
ROA(5y)3.37%
ROE(3y)-2.25%
ROE(5y)3.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-74.13%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.32 | ||
| Debt/FCF | 1.74 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 902.95% | ||
| Current Ratio | 2 | ||
| Quick Ratio | 2 | ||
| Altman-Z | 1.84 |
F-Score8
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)100.1%
EPS 3Y-72.17%
EPS 5YN/A
EPS Q2Q%-618.05%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-1.94%
Revenue growth 3Y4.21%
Revenue growth 5Y-5.01%
Sales Q2Q%-10.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y268.27%
FCF growth 3Y-47.34%
FCF growth 5YN/A
OCF growth 1Y268.27%
OCF growth 3Y-47.34%
OCF growth 5YN/A